Literature DB >> 30384543

[Metabonomics study on hepatoprotective effect of Schisandrae Chinensis Fructus based on UPLC-Q-TOF-MS].

Yong-Feng Zhou1, Ming Niu1, Ji-Xiang Fang1, Yan-Qin Ma1, Yuan-Yuan Cui1, Yi Dong1, Rong-Rong Zhang1, Jia-Bo Wang1, Ping Zhang1.   

Abstract

To investigate the hepatoprotective effect of Schisandrae Chinensis Fructus (SCF) on CCl₄-induced liver injury, observe its effect on serum metabolites, explore its scientific connotation in liver preservation and find the biomarkers for hepatoprotective effect of SCF. Liver injury model was established by using CCl₄. The pathological sections of liver tissues were observed and the contents of alanine transaminase (ALT) and aspartate transaminase (AST) in serum were determined. The metabolic skills were adopted based on ultra performance liquid chromatography time-of-flight mass spectrometry (UPLC-Q-TOF-MS), principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA) for screening and identification of biomarkers related to liver injury. The results showed the metabolites in blank group, model group and administration group could be easily distinguished, 50 differential compounds were identified and 7 possible metabolic pathways of liver protection were enriched. In this experiment, the hepatoprotective effect of SCF was verified, and the related metabolic pathways such as amino acid metabolism, vitamin metabolism and glycerophospholipid metabolism were discussed. Copyright© by the Chinese Pharmaceutical Association.

Entities:  

Keywords:  Schisandrae Chinensis Fructus ; UPLC-Q-TOF-MS ; hepatoprotective ; metabonomics

Mesh:

Substances:

Year:  2018        PMID: 30384543     DOI: 10.19540/j.cnki.cjcmm.20180516.004

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  1 in total

1.  Comparison of Chemical Constituents in Pseudostellariae Radix with Different Dosage Forms Based on HPLC-Q-Exactive Orbitrap/MS Combined with Multivariate Statistical Analysis.

Authors:  Yujiao Hua; Xiaoyuan Liu; Fen Xie
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-08       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.